bms-919373 + rosuvastatin

**BMS-919373 + rosuvastatin** is a combination of two small molecule drugs: BMS-919373, an investigational selective voltage-gated potassium channel Kv1.5 (IKur) blocker, and rosuvastatin, a marketed HMG-CoA reductase inhibitor (statin). BMS-919373 was developed by Bristol Myers Squibb with the primary indication of reducing atrial fibrillation burden by selectively inhibiting Kv1.5, thus affecting cardiac electrical activity. Rosuvastatin lowers cholesterol by inhibiting HMG-CoA reductase and is widely indicated for hyperlipidemia and cardiovascular risk reduction. This specific combination has been studied in clinical trials to evaluate drug-drug interactions, specifically assessing how BMS-919373 affects the pharmacokinetics of rosuvastatin in healthy subjects. BMS-919373’s development was discontinued after Phase 2 trials for atrial fibrillation; rosuvastatin remains approved and marketed worldwide for lipid management and prevention of cardiovascular disease[1][3][4][5][6].

Other names

rosuvastatin